Prosthetic Joint Infections Treatment Market to Reach USD 258.36 Million by 2034, Growing from USD 141.72 Million in 2025 - SRI

London, UK - August 2026 | Strategic Revenue Insights Inc. - A new CMS payment model took effect on January 1, 2026 that puts hospitals on the hook, financially, for avoidable readmissions and post-acute outcomes across an entire lower extremity joint replacement episode, a structural shift that is pushing infection prevention and management further up the list of hospital priorities. The Transforming Episode

https://www.strategicrevenueinsights.com/industry/prosthetic-joint-infections-treatment-market

Accountability Model runs through December 31, 2030 for selected hospitals and lands alongside a new CMS reimbursement code for advanced periprosthetic joint infection diagnostics, together reshaping how infection risk gets budgeted and treated. Against this backdrop, the global prosthetic joint infections treatment market, valued at USD 141.72 million in 2025, is forecast to reach USD 258.36 million by 2034, growing at a CAGR of 6.90% during the 2026-2034 period, according to a new report from Strategic Revenue Insights Inc. The findings are led by lead analyst Kamrul Hasan, and the report's conclusions draw on primary interviews with orthopedic surgeons, hospital procurement teams, and other relevant healthcare stakeholders, supplemented by secondary research across Asia Pacific, North America, Latin America, Europe, and the Middle East & Africa.

Key Takeaways

The prosthetic joint infections treatment market is valued at USD 141.72 million in 2025 and is projected to reach USD 258.36 million by 2034, growing at a CAGR of 6.90%.

Antibiotics hold the largest treatment type share given their critical role in infection management, while Revision Surgery is the fastest-growing segment, driven by advancements in surgical technique.

New CMS reimbursement coding for an 11-biomarker periprosthetic joint infection test with an algorithmic probability score is creating a formal pathway for faster, more precise treatment selection.

North America leads the market due to advanced healthcare infrastructure and high prevalence of joint replacement surgeries, while Asia Pacific is the fastest-growing region on rising healthcare investment and awareness.

Zimmer Biomet, Stryker, and DePuy Synthes are named among the leading competitors shaping the market.

Full report access: https://www.strategicrevenueinsights.com/industry/prosthetic-joint-infections-treatment-market

Policy and Diagnostics Are Redrawing the Treatment Pathway

Reimbursement policy is becoming as important a growth lever as clinical need in this market. CMS's mandatory Transforming Episode Accountability Model, which began January 1, 2026, covers lower extremity joint replacement episodes and explicitly targets avoidable readmissions and higher-value post-acute management, likely increasing hospital demand for products and care pathways that prevent or manage prosthetic joint infection within fixed episode budgets. Alongside this, CMS added HCPCS code 0601U effective January 1, 2026 for an 11-biomarker periprosthetic joint infection test with an algorithmic probability score, giving providers a formal coding and compliance pathway for advanced diagnostic workups that can support faster treatment selection and revision planning.

The scale of the underlying patient population continues to expand the addressable market. The AAOS/AAHKS American Joint Replacement Registry's 2025 Annual Report analyzed more than 4.4 million total hip and knee arthroplasty procedures submitted by more than 5,000 surgeons, a large and still-growing procedural base that increases the absolute number of patients at risk for infection and in need of revision, local antibiotic delivery, or anti-biofilm treatment.

Regulatory expansion and manufacturing investment are widening both geographic reach and supply reliability. Biocomposites received EU MDR certification for STIMULAN combination-antibiotic use in February 2026 and gained expanded approval in India in November 2025 to mix STIMULAN Rapid Cure with a wider range of antibiotics and antifungals, while Zimmer Biomet advanced PMDA-approved iodine-treated hip implants in Japan. Biocomposites also brought its SYNICEM bone cement products to the UK in February 2026 and said it is doubling global production capacity to one million packs per year to help meet NHS demand during a supply shortage, supporting more reliable access to the fixation materials used in revision arthroplasty and infection-risk management.

Market Segmentation

By treatment type, Antibiotics hold the largest share given their critical role in managing infections, while Revision Surgery is the fastest-growing segment, driven by advancements in surgical technique and a rising number of cases requiring revision procedures.

By infection type, Early infections, which occur within the first few weeks after surgery, are the most common and require prompt intervention, while Late infections, often associated with biofilm formation years after the initial surgery, require more aggressive treatment approaches and are driving demand for advanced diagnostic tools.

By joint type, Hip and Knee joints account for the majority of joint replacement surgeries and represent the largest segments, while Shoulder joint infections, though less common, are pushing demand for specialized treatment approaches as surgical techniques and targeted therapies advance.

By end user, Hospitals account for the largest share, driven by advanced medical facilities and the ability to manage complex cases, while Ambulatory Surgical Centers (ASCs) are gaining traction as a cost-effective, convenient option for joint replacement care.

Regional Outlook

North America dominates the prosthetic joint infections treatment market due to its advanced healthcare infrastructure and high prevalence of joint replacement surgeries. Asia Pacific is the fastest-growing region, driven by increasing healthcare investments and rising awareness of advanced medical treatments. Latin America, Europe, and the Middle East & Africa round out the report's covered regions, with Europe additionally shaped by recent regulatory milestones such as Biocomposites' EU MDR certification for STIMULAN.

Competitive Landscape

Zimmer Biomet is named as a leading player known for its comprehensive range of orthopedic products and continuous innovation across developed and emerging markets, including its iodine-treated iTaperloc Complete and iG7 Hip System. Stryker is recognized for its robust R&D capabilities and focus on improving patient outcomes through advanced technologies, while DePuy Synthes, part of Johnson & Johnson, offers a broad orthopedic and neurosurgical portfolio with an emphasis on quality and safety. Smith & Nephew is noted for advanced wound management and surgical devices, Heraeus Medical specializes in biomaterials and infection management solutions, and Exactech focuses on innovative orthopedic implants and surgical instruments. Additional named players include MicroPort, Biometrix, OsteoRemedies, and Tecres, alongside Biocomposites, which has advanced its STIMULAN and SYNICEM antibiotic-carrier and bone cement platforms.

Market Restraints

Stringent regulatory requirements governing the approval and commercialization of medical treatments pose a challenge, as companies must navigate complex, time-consuming, and costly processes to bring products to market. The high cost of treatment is also a restraint, potentially limiting accessibility in low-income regions where healthcare resources are scarce, while the ongoing threat of antibiotic resistance adds pressure for continued investment in new and more effective drugs.

Related Reports

https://www.strategicrevenueinsights.com/industry/protective-wrapping-paper-market

https://www.strategicrevenueinsights.com/industry/bioplastics-for-packaging-market

https://www.strategicrevenueinsights.com/industry/horizontal-form-fill-seal-hffs-machines-market

https://www.strategicrevenueinsights.com/industry/antimony-free-film-market

https://www.strategicrevenueinsights.com/industry/eva-coated-film-market

Frequently Asked Questions

What is driving growth in the prosthetic joint infections treatment market?
Key drivers include the increasing prevalence of joint replacement surgeries, advancements in medical technology, and the rising geriatric population.

What is the largest segment in the prosthetic joint infections treatment market?
Antibiotics hold the largest treatment type share, owing to their critical role in infection management.

Which region is expected to grow fastest in the prosthetic joint infections treatment market?
Asia Pacific is expected to witness the highest growth rate, driven by increasing healthcare investments and rising awareness.

Who are the leading companies in the prosthetic joint infections treatment market?
Leading companies named in the report include Zimmer Biomet, Stryker, and DePuy Synthes, alongside Smith & Nephew, Heraeus Medical, Exactech, MicroPort, Biometrix, OsteoRemedies, Tecres, and Biocomposites.

Media Contact Information
Company Name: Strategic Revenue Insights Inc.
Contact Person: Rohit Bhisey
Email: sales@strategicrevenueinsights.com
Phone: +44 7877403352
Address: Suite 10, Capital House, 61 Amhurst Road, E8 1LL
City: London
State: London
Country: United Kingdom

About Strategic Revenue Insights Inc.

Strategic Revenue Insights Inc., a distinguished subsidiary of SRI Consulting Group Ltd, stands as a premier provider of data-driven market intelligence, empowering organizations globally to navigate complex business landscapes with confidence and precision. Headquartered in London, United Kingdom, our firm specializes in delivering comprehensive syndicated research reports, bespoke consulting solutions, and actionable strategic insights that enable clients to make informed, forward-thinking decisions in an increasingly competitive marketplace.

Our dedicated team of accomplished analysts, strategically positioned in London with an extensive global network, maintains continuous vigilance over evolving market dynamics, identifying emerging trends and uncovering high-potential growth opportunities that drive sustained client success. As an integral component of SRI Consulting Group Ltd, we uphold unwavering commitments to analytical accuracy, clarity of presentation, and practical applicability, assisting organizations in navigating competitive terrain, optimizing strategic initiatives, and accelerating revenue trajectories.

Through the integration of rigorous research methodologies with profound industry expertise, Strategic Revenue Insights Inc. delivers comprehensive market perspectives that generate measurable outcomes and establish enduring competitive advantages for our clients across diverse sectors and geographies.

Corporate Websites:
www.strategicrevenueinsights.com
www.strategicpackaginginsights.com
www.sriconsultinggroupltd.com
https://strategicrevenueinsights.blog/
https://medium.com/@strategic-revenue-insights.inc
https://www.strategicrevenueinsights.com/press-releases

This release was published on openPR.